Melinta Therapeutics will be presenting clinical evidence from the Baxdela (delafloxacin) clinical program at the 27th European Congress of Clinical Microbiology and Infectious Diseases. Baxdela, an investigational fluoroquinolone, has completed Phase 3 testing and is the subject of a New Drug Application currently under review at the U.S. Food and Drug Administration for the treatment of patients with serious hospital-treated skin infections … more

Melinta and its collaborators have been invited to make a presentation on the company’s development of a novel class of antibiotics called pyrrolocytosines during a moderated e-poster session.

These compounds are based on a molecular scaffold that was rationally designed for high binding affinity to a site on the bacterial ribosome not exploited by other commercially available antimicrobials. By honing the scaffolds’ shapes and polarities, Melinta scientists have created hundreds of pyrrolocytosine compounds that demonstrate potent activity against Gram-negative bacteria, do not share cross-resistance with current therapies and – in their best examples – are not impacted by efflux, a major problem with resistant Gram-negative bacteria … more